Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.
The reliability of cerebrospinal fluid (CSF)-tau and CSF-beta-amyloid assays for diagnosis of Alzheimer's disease and other dementing disorders such as frontotemporal dementia (FTD), dementia with Lewy bodies (DLB) and Creutzfeldt-Jakob disease (CJD) is reviewed. CSF assessment of the two proteins is useful in early diagnosis of AD and to differentiate it from FTD and DLB. Extremely high CSF-tau levels can discriminate CJD from AD.
Vanmechelen
E
E
Innogenetics NV, Industriepark Zwijnaarde 7, Box 4, B-9052, Ghent, Belgium. eugeevme@innogenetics.com
Vanderstichele
H
H
Hulstaert
F
F
Andreasen
N
N
Minthon
L
L
Winblad
B
B
Davidsson
P
P
Blennow
K
K
D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid*; D003704:Dementia / Q000134:cerebrospinal fluid* / Q000175:diagnosis; D006801:Humans; D010446:Peptide Fragments / Q000134:cerebrospinal fluid*; D013997:Time Factors; D016875:tau Proteins / Q000134:cerebrospinal fluid*
D016229:Amyloid beta-Peptides; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins